Pre-Exposure Prophylaxis

Preventing HIV with One Pill a Day: Using PrEP in Clinical Practice

By | Education, Events, Fenway Health Newsroom, Fenway News, HIV/AIDS, The Fenway Institute | No Comments
The Fenway Institute and the National LGBT Health Education Center are excited to announce an upcoming educational conference for medical providers about the usage of on PrEP (pre-exposure prophylaxis) for HIV prevention. PrEP, also known by the brand name Truvada, is a once-daily HIV prevention pill with the potential to make a significant contribution to ending the HIV/AIDS epidemic. You are invited to attend a continuing education conference focused on teaching providers how to incorporate PrEP into their clinical practice. The conference is for any providers – including primary care or other relevant providers – who are interested in becoming 
Read More

Vacation Study Examines Efficacy of Short-Term PrEP Use

By | Fenway Health Newsroom, HIV/AIDS, HIV/AIDS, The Fenway Institute | No Comments
As the weather grows colder, many people are starting to plan their 2016 vacations. Among the TSA screenings and hotel ratings, there is one rarely discussed aspect of travel planning and safety: sexual health. Research has shown that many men who have sex with men (MSM) have periods of elevated HIV risk that often coincide with times away from home or vacations. The often casual and spontaneous nature of sexual encounters while traveling can result in unprotected sex and, in doing so, raise one’s risk of HIV infection. Pre-exposure prophylaxis (PrEP), a daily pill to prevent HIV infection, is a 
Read More

New Campaign Highlights Benefits Of Daily PrEP Use

By | AIDS Action Committee, Fenway Health Newsroom, HIV Prevention, HIV/AIDS | No Comments
The AIDS Action Committee is pleased to announce the launch of a new advertising campaign that aims to educate the public on the benefits of pre-exposure prophylaxis (PrEP) in the fight against HIV. Also commonly known by the brand name Truvada, PrEP is a daily pill that, when taken daily, has proven to be 99% effective in preventing HIV infection. The Talk PrEP campaign hopes to raise public awareness of PrEP’s efficacy and encourage people to start conversations with their friends, family, and doctors about this life-saving drug. Anyone who is HIV-negative, does not have degenerative kidney or liver disease 
Read More

HIV/STD Prevention and Treatment Research Update To Highlight Medical Advances On November 17

By | AIDS 2014, Events, Fenway Health Newsroom, HIV/AIDS | No Comments
30 years after the start of the AIDS epidemic, the medical research community has made great strides in improving prevention and treatment methods – and that work continues today. On November 17, Fenway Health is proud to host an HIV/STD Prevention and Treatment Research Update. This event, which occurs at least once a year, brings together some of the leading HIV/AIDS and STD authorities to share new exciting breakthroughs and research findings with the community, as well as to outline where HIV/STD prevention and treatment is headed next. During the evening, experts in the fields of HIV and STD research 
Read More
Male Couple

Improving PrEP adherence by leveraging the strengths of male couples’ relationships: the “Couples PrEP” Study

By | Fenway Health Newsroom, HIV/AIDS, The Fenway Institute | No Comments
Men who have sex with men continue to be the highest risk group for HIV transmission in the United States.1 A large proportion of new HIV infections among men who have sex with men (between one- and two-thirds) are attributed to sexual contact with primary or main partners.2,3 Understanding the contexts of men’s sexual and intimate relationships may help improve the efficacy of prevention interventions.4-6 While antiretroviral pre-exposure prophylaxis (PrEP) has been shown to be a promising biomedical HIV prevention strategy for many men, the efficacy of oral PrEP regimens depends on taking the medication consistently, often referred to as 
Read More